Dermatology Week 1 Practice Exam

Baricitinib dosing is set to balance how well it suppresses inflammatory signaling with the need to minimize safety risks. The dose described here is 2 mg taken by mouth once daily. This amount provides meaningful clinical effect for many inflammatory skin conditions while maintaining a favorable safety profile for most adults. In some cases, clinicians may increase to 4 mg daily if the response is not adequate, but that higher dose carries greater risks, including infections and blood abnormalities. A lower dose like 1 mg is typically subtherapeutic for these conditions, and an 8 mg daily dose is not a standard approved option. Renal function can also influence dosing, with reductions needed for impaired kidney function according to the labeling.